Preliminary evaluation of the radiotherapeutic efficacy of I-atorvastatin in rats with hepatocellular carcinoma
Nuclear Science and Techniques, ISSN: 2210-3147, Vol: 31, Issue: 11
2020
- 4Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
As one of the most critical types of cancer, hepatocellular carcinoma (HCC) affects many people worldwide. This study demonstrated the prospective use of atorvastatin, a drug that inhibits the mevalonate pathway, causing hypolipidemia, as a carrier to deliver the iodine-131 (I) isotope to liver tissues for HCC radiotherapy. The atorvastatin radioiodination method was optimized for utilizing the I isotope. The radiochemical quality and the in vitro stability of the generated [I]atorvastatin were investigated. In addition, the biodistribution experiments of [I]atorvastatin were evaluated in both normal and HCC-induced rat models. [I]atorvastatin was produced at a maximum radiochemical yield of 86.7 ± 0.49%. The [I]atorvastatin solution purified via high-performance liquid chromatography showed good in vitro stability for 12 h after tagging. Biodistribution analyses revealed remarkable liver targeting capacity of [I]atorvastatin and good localization of I in liver tissues. Overall, the encouraging biochemical profile and histopathological findings have been reported, and preliminary investigations on the possible use of [I]atorvastatin as a radiotracer and its impact on HCC radiotherapy in rats show promise.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85094959153&origin=inward; http://dx.doi.org/10.1007/s41365-020-00819-1; http://link.springer.com/10.1007/s41365-020-00819-1; http://link.springer.com/content/pdf/10.1007/s41365-020-00819-1.pdf; http://link.springer.com/article/10.1007/s41365-020-00819-1/fulltext.html; http://sciencechina.cn/gw.jsp?action=cited_outline.jsp&type=1&id=6859199&internal_id=6859199&from=elsevier; https://dx.doi.org/10.1007/s41365-020-00819-1; https://link.springer.com/article/10.1007/s41365-020-00819-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know